

Late Lodgment of Change of Director's Interest Notice

The attached Appendix 3Y "Change of Director's Interest Notice" for Mr. Otto Buttula, Mr. Trevor Lockett and Mr. Lou Panaccio, are lodged due to the cessation of options resulting from the Company not meeting the objectives under the 2020 ESOP.

The Company advises that:

1. The Appendix 3Y was lodged late due to an administrative oversight. As soon as the oversight was identified, the attached Appendix 3Y was lodged with the ASX;
2. The Company and the Directors are aware of their obligations under ASX Listing Rule 3.19A and 3.19B to provide the necessary information to the Company to meet its disclosure requirements; and
3. The Company believes that its current practices are adequate to ensure compliance with the ASX Listing Rules.

- ENDS -

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via investor@rhythmbio.com or on +61 3 8256 2880:

Mr Paul Smith CFO & Company Secretary

About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the company on LinkedIn and Twitter.

About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.

Rhythm Biosciences Ltd
ACN 619 459 335
ASX: RHY

www.rhythmbio.com

Australian Registered Address
Bio21 Molecular Science & Biotechnology Institute
30 Flemington Road
Parkville VIC 3010 Australia

T +61 3 8256 2880
E info@rhythmbio.com

Directors
Otto Buttula
Trevor Lockett
Rachel David
Louis Panaccio
Sue MacLeman

Executive Chairman
Executive Director
Non-Executive Director
Non-Executive Director
Non-Executive Director

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Rhythm Biosciences Limited
ABN	59 619 459 335

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Otto Buttula
Date of last notice	15 May 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	1) Newfound Investments Pty Ltd <Newfound Super Fund A/C> 2) Webinvest Pty Ltd <OLSB Unit A/C>
Date of change	30 June 2023

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	1) Newfound Investments Pty Ltd <Newfound Super Fund A/C> 6,819,729 fully paid ordinary shares (ASX: RHY) 134,167 Unlisted \$1.80 options (ASX: RHYAL) expiring 31 July 2024 1,500,000 Unlisted \$1.80 options (ASX: RHYAI) expiring 31 July 2024 2) Webinvest Pty Ltd <OLSB Unit A/C> 17,291,667 fully ordinary paid shares (ASX: RHY) 208,333 Unlisted \$1.80 options (ASX: RHYAL) expiring 31 July 2024
Class	Unlisted options (ASX: RHYAI) expiring 31 July 2024
Number acquired	NIL
Number disposed	Cessation of 500,000 Options due to conditions not being met.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Refer to notice lodged with ASX on 30 June 2023 for further information.
No. of securities held after change	3) Newfound Investments Pty Ltd <Newfound Super Fund A/C> 6,819,729 fully paid ordinary shares (ASX: RHY) 134,167 Unlisted \$1.80 options (ASX: RHYAL) expiring 31 July 2024 1,000,000 Unlisted \$1.80 options (ASX: RHYAI) expiring 31 July 2024 4) Webinvest Pty Ltd <OLSB Unit A/C> 17,291,667 fully ordinary paid shares (ASX: RHY) 208,333 Unlisted \$1.80 options (ASX: RHYAL) expiring 31 July 2024
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cessation of 500,000 unlisted options due to conditions not being met

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	#N/A
Nature of interest	#N/A
Name of registered holder (if issued securities)	#N/A
Date of change	#N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	#N/A
Interest acquired	#N/A
Interest disposed	#N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	#N/A
Interest after change	#N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	#N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	#N/Ao
If prior written clearance was provided, on what date was this provided?	#N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Rhythm Biosciences Limited
ABN	59 619 459 335

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Lou Panaccio
Date of last notice	09 January 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Tercus Pty Ltd
Date of change	30 June 2023
No. of securities held prior to change	Held by Beneficial interest through Tercus Pty Ltd: 830,000 fully paid ordinary shares (ASX: RHY) 10,000 unlisted options exercisable at \$1.80 on or before 31 July 2024 (ASX: RHYAL) 112,500 unlisted option exercisable at \$1.80 on or before 31 July 2024 (ASX: RHYAI).

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Unlisted options (ASX: RHYAI) expiring 31 July 2024
Number acquired	Nil
Number disposed	Cessation of 37,500 Options due to conditions not being met.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Refer to notice lodged with ASX on 30 June 2023 for further information.
No. of securities held after change	Held by Beneficial interest through Tercus Pty Ltd: 830,000 fully paid ordinary shares (ASX: RHY) 10,000 unlisted options exercisable at \$1.80 on or before 31 July 2024 (ASX: RHYAL) 75,000 unlisted option exercisable at \$1.80 on or before 31 July 2024 (ASX: RHYAI).
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cessation of 37,500 unlisted options due to conditions not being met

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	#N/A
Nature of interest	#N/A
Name of registered holder (if issued securities)	#N/A
Date of change	#N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	#N/A
Interest acquired	#N/A
Interest disposed	#N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	#N/A
Interest after change	#N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	#N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	#N/A
If prior written clearance was provided, on what date was this provided?	#N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Rhythm Biosciences Limited
ABN	59 619 459 335

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Trevor Lockett
Date of last notice	09 January 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	30 June 2023
No. of securities held prior to change	166,000 fully paid ordinary shares held by Mrs Linda Jane Lockett & Dr Trevor John Lockett (ASX: RHY) 1,125,000 unlisted options held by Mrs Linda Jane Lockett & Dr Trevor John Lockett to acquire fully paid ordinary shares exercisable at \$0.20 on or before 14 September 2023 (ASX: RHYAH). 2,000 unlisted options exercisable at \$1.80 on or before 31 July 2024 (ASX: RHYAL). 375,000 unlisted option exercisable at \$1.80 on or before 31 July 2024 (ASX: RHYAI).

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Unlisted options (ASX: RHYAI) expiring 31 July 2024
Number acquired	Nil
Number disposed	Cessation of 125,000 Options due to conditions not being met.
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Refer to announcement lodged with ASX on 30 June 2023 for further information.
No. of securities held after change	166,000 fully paid ordinary shares held by Mrs Linda Jane Lockett & Dr Trevor John Lockett (ASX: RHY) 1,125,000 unlisted options held by Mrs Linda Jane Lockett & Dr Trevor John Lockett to acquire fully paid ordinary shares exercisable at \$0.20 on or before 14 September 2023 (ASX: RHYAH). 2,000 unlisted options exercisable at \$1.80 on or before 31 July 2024 (ASX: RHYAL). 250,000 unlisted option exercisable at \$1.80 on or before 31 July 2024 (ASX: RHYAI).
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Cessation of 125,000 unlisted options due to conditions not being met

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	#N/A
Nature of interest	#N/A
Name of registered holder (if issued securities)	#N/A
Date of change	#N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	#N/A
Interest acquired	#N/A
Interest disposed	#N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	#N/A
Interest after change	#N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	#N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	#N/A
If prior written clearance was provided, on what date was this provided?	#N/A

⁺ See chapter 19 for defined terms.